22 results about "Degranulation" patented technology

This invention provides a small molecule inhibitor targeting the FcεRIγ subunit and its application. It discovers that erythrophenol can act as a small molecule inhibitor targeting the FcεRIγ subunit, thereby inhibiting the occurrence of allergic reactions. This invention confirms the direct binding interaction between erythrophenol and the FcεRIγ subunit using SPR and CETSA techniques, revealing that erythrophenol can target and inhibit the FcεRIγ subunit. Furthermore, this invention finds that erythrophenol can significantly inhibit the release of IgE signal-induced β-aminoglycosidase in mast cells, exhibiting a significant ability to inhibit IgE signal-mediated mast cell degranulation and suppress mast cell activation-mediated allergic reactions. This fully demonstrates that erythrophenol, as an inhibitor targeting the FcεRIγ subunit, holds promise as the first inhibitor to induce FcεRIγ subunit degradation in anti-type I allergic diseases, and has broad application prospects for further use in anti-allergy treatment.

The present invention relates to a mouse SCF-neutralizing antibody and uses thereof. Specifically, the present invention relates to an antibody for neutralizing mouse SCF, comprising a heavy and a light chain of specific sequences, or an antigen-binding fragment thereof. A novel antibody is constructed for neutralizing SCF to inhibit SCF / c-kit signaling, leading to the development of a therapeutic agent for inhibiting abnormal angiogenesis, suppressing differentiation, proliferation, and degranulation of mast cells, and restraining proliferation of smooth muscle cells.

The invention provides a preparation process of an anti-allergic health food, and relates to the technical field of health food preparation. The production process of the anti-allergic health-care food comprises the following steps: preparing the following raw materials: herba cistanche, radix astragali, rhizoma polygonati, a bupleurum chinense leaf extract, a dandelion extract, honey and potassium sorbate, wherein the addition ratio of the bupleurum chinense leaf extract to the dandelion extract is 1: 2; cistanche deserticola, astragalus membranaceus and rhizoma polygonati are mixed, excessive water is added for soaking, reflux extraction and filtration are performed, filtrate is combined, and an extracting solution is obtained. By adding the bupleurum chinense leaf extract and the dandelion extract into an extracting solution of traditional Chinese medicinal materials such as astragalus membranaceus, the ratio of IgG1 / IgG2a can be effectively reduced, namely Th1 type immune response is relatively enhanced, Th2 type response is relatively weakened, allergen-specific IgE antibodies generated by B cells are correspondingly reduced, degranulation reaction and release of inflammatory mediators such as histamine are relieved, and the anti-inflammatory effect is achieved. The anaphylactic reaction is effectively relieved.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a compound in preparation of an anti-allergic medicine. The degranulation inhibition effect is verified through a mast cell in-vitro culture model, the overall anti-allergic activity is verified by combining an animal allergy model, and a series of experiments prove that the compound A33 can inhibit I-type anaphylaxis (such as ear and subcutaneous anaphylaxis) mediated by an IgE antibody. Different from a traditional anti-allergic drug (such as an antihistamine drug), the compound A33 is used for preventing release of media such as TNF-alpha and IL-6 from the source in an anaphylactic reaction starting link that the compound A33 directly inhibits mast cell degranulation in allusion to downstream blocking of an allergic medium, so that the compound A33 is introduced into the field of anti-allergic product research; a new candidate strategy with a clear targeting mechanism and an experimental basis is provided for prevention and / or treatment of allergic diseases, and the application value in anti-allergic drugs, cosmetics or daily chemical products is wide.

Compositions and methods for treating diseases and conditions mediated by the high affinity IgE receptor (FcεRI) are provided. Also provided are antisense oligomers for modulating splicing of mRNA encoding a MS4A6A protein, optionally in addition to antisense oligomers for modulating splicing of mRNA encoding the FcεRIβ protein, thereby down-regulating cell-surface expression of FcεRI, and uses of the antisense oligomers for inhibiting mast cell degranulation, cytokine release, migration, and proliferation; for inhibiting anaphylaxis reactions in individuals, for treating allergic conditions in individuals, for reducing the incidence of allergic reactions in individuals, for treating individuals at risk of developing anaphylactic reactions, and for treating mast cell-related diseases in individuals.

This invention discloses an antipruritic gel containing 3-hydroxydecanoic acid microemulsion and its preparation method. The gel combines the natural antipruritic ingredient 3-hydroxydecanoic acid and peppermint oil. By preparing it into a microemulsion form, nano-sized droplets are combined with skin absorption enhancers and gel sustained-release agents, thereby improving transdermal absorption efficiency and prolonging the residence time in the skin to achieve a long-lasting antipruritic effect. 3-hydroxydecanoic acid exerts its antipruritic effect through anti-inflammatory action, blocking pruritus signaling pathways, and reducing mast cell degranulation. This antipruritic gel is stable at room temperature, easy to use, and suitable for relieving skin itching caused by mosquito bites, histamine, or non-histamine substances.

The application provides a kind of low sensitization of penaeus vannamei and its preparation method and application, belong to food biotechnology field.The application uses fucoidan to treat penaeus vannamei by covalent modification, after treatment, protein spatial conformation has changed significantly, allergen epitope is hidden.After BALB / c mouse sensitization model and RBL-2H3 cell degranulation model test shows, the sensitization of covalent modification penaeus vannamei decreases by 72.88%, low sensitization penaeus vannamei can inhibit mast cell degranulation and increase the threshold of sensitization, but still has immunogenicity.Through the construction of BALB / c mouse oral tolerance model, it is found that low sensitization penaeus vannamei can significantly alleviate the multiple immunoglobulin-mediated hypersensitivity caused by mouse allergy, which proves that low sensitization penaeus vannamei has auxiliary effect on oral tolerance, can promote oral tolerance ability, can be used as an effective immune tolerance agent for shrimp allergy patients.

The present application provides a dendrobium officinale polysaccharide extract, a preparation method and an application, the dendrobium officinale polysaccharide extract is with dendrobium officinale stem as raw material, is extracted by purified water reflux, is precipitated by ethanol, is deproteinized by Sevag, is decolorized and is deashed and is obtained by gel / film separation and purification, the mass percentage content of polysaccharide in the extract is 50-95wt%, the average molecular weight is 10-300 kDa, and the monosaccharide component includes mannose, glucose, galactose, fucose, rhamnose and arabinose.The dendrobium officinale polysaccharide extract provided by the present application has immune activation effect on natural killer cells, can promote the NK cell CD107a degranulation reaction and the expression of IFN-gamma, perforin and granzyme B in a dose-dependent manner, up-regulates the NKG2D related pathway, thereby activating the NK cell function and enhancing the killing activity of NK cells on tumor target cells such as K562.

This invention discloses a fusion peptide with synergistic anti-allergic effects, an anti-LTB4 monoclonal antibody, and an anti-allergic drug composition thereof. The fusion peptide is composed of peptide A, which inhibits histamine release, and peptide B, which blocks mast cell activation signals, covalently linked by a linker peptide, which can synergistically inhibit mast cell activation. The anti-LTB4 monoclonal antibody can specifically bind to LTB4, blocking its mediated inflammatory response. Combining the fusion peptide, the anti-LTB4 monoclonal antibody, and myricetin, which has antioxidant activity, forms a multi-target drug composition that can synergistically inhibit allergic reactions from multiple aspects, such as inhibiting mast cell degranulation, blocking the action of inflammatory mediators, and clearing oxidative stress products. In vitro cell experiments and OVA-induced allergic asthma mouse models have demonstrated that the anti-allergic effect of this composition is significantly better than that of a single component, and it has no obvious toxicity, providing a new candidate drug for the efficient treatment of allergic diseases.

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a traditional Chinese medicine composition for treating allergic rhinitis and a preparation method of the traditional Chinese medicine composition. 5 to 20 parts of astragalus polysaccharide; 2 to 8 parts of glycyrrhizin; 1 to 5 parts of ceramide; 3-10 parts of a radix angelicae dahuricae extract; 3-10 parts of a cocklebur fruit extract; 5 to 15 parts of baicalin; and 1-5 parts of magnolia flower volatile oil. Wherein the active component of the supercritical extract of the coptis chinensis paste can correct proportional imbalance of immune cells from a transcriptional level, and can also cooperate with baicalin to inhibit phosphorylation and nuclear translocation of related signal pathways, inhibit effector cell activation degranulation and reduce expression and secretion of proinflammatory factors; the fructus xanthii extract and the flos magnoliae volatile oil can quickly relieve acute allergy symptoms, and the plant ceramide repairs the physical barrier of nasal mucosa in a targeted manner, so that the problems that in the prior art, a modern conversion process of a classic prescription is difficult in quality control, the preparation lacks local targeting, and the research on a compound mechanism is shallow are solved.

The invention provides a dendrobium officinale polysaccharide extract as well as a preparation method and application thereof.The dendrobium officinale polysaccharide extract is prepared from dendrobium officinale stems as a raw material through purified water reflux extraction, ethanol precipitation, Sevag deproteinization, decoloration and deliming and gel / membrane separation and purification, the mass percentage content of polysaccharide in the extract is 50-95 wt%, the average molecular weight is 10-300 kDa, and the content of polysaccharide in the extract is 50-95%. The monosaccharide components comprise mannose, glucose, galactose, fucose, rhamnose and arabinose. The dendrobium officinale polysaccharide extract provided by the invention has an immune activation effect on natural killer cells, can dose-dependently promote the degranulation reaction of NK cells CD107a and the expression of IFN-gamma, perforin and granzyme B, and up-regulate NKG2D related pathways, so that the functions of the NK cells are activated, and the killing activity of the NK cells on tumor target cells such as K562 is enhanced.

The invention belongs to the technical field of traditional Chinese medicines, and particularly provides a Hangzhou thistle extract for treating atopic dermatitis (AD), and the Hangzhou thistle extract is prepared by the following steps: weighing Hangzhou thistle, adding an alcoholic solution for extraction, adsorbing and eluting an extracting solution by using resin, and collecting eluent to obtain the Hangzhou thistle extract. When the Hangzhou thistle extract provided by the invention is externally applied to a skin lesion part, AD symptoms can be effectively improved, including improvement of skin tissue form, promotion of skin lesion part recovery, reduction of scratching times, reduction of ear swelling degree and spleen index, reduction of inflammatory factor level, reduction of mastocyte number and inhibition of degranulation of mastocyte; the inflammatory response of atopic dermatitis is improved by regulating and controlling a TLR4 / NF-kappa B pathway. The problem of poor patient compliance caused by tedious operation of traditional Chinese medicine compound oral administration is solved. A novel, effective and safe treatment mode is provided for AD treatment, application and development of Hangzhou thistle are greatly promoted, and a new strategy is provided for local resource development and utilization and economic development.

The application provides a cell identification kit and a use method and application thereof in identifying mast cells, and relates to the technical field of cell identification. The cell identification kit comprises CD117 antibody conjugated magnetic microparticles, CD16 antibody conjugated magnetic microparticles and Fc epsilon R1 alpha antibody conjugated magnetic microparticles, and FcR blocking agent and eluent. The cell identification kit can be used to identify one or more of CD117, Fc epsilon R1 alpha and CD16 on the surface of cells, and target cells with a purity of at least 90% can be obtained. The application is applied to identifying whether a cell is CD117 + Fc epsilon R1 alpha + CD16 ‑ mast cells, target cells with a purity higher than 95% can be obtained, the degranulation rate of mast cells is improved, and the technical problem of a low degranulation rate of mast cells obtained by a mast cell identification method in the prior art is solved.

Various embodiments of the invention provide compositions of tumor infiltrating lymphocytes (TILs) enriched in tumor reactive cells, methods for manufacturing TILs enriched in tumor reactive cells and methods and uses of the provided enriched tumor reactive TILs for treating cancer in a human or other subject. Among the provided embodiments of TIL compositions may include those that exhibit substantial tumor reactivity activity, including degranulation and the ability to express one or more of IFN-gamma and TNF-alpha, in response to antigen presenting cells presenting neo antigenic peptides.

The application discloses a new water-soluble phenolic acid salviamarinic acid B extracted from radix salviae miltiorrhizae, adopts a C48 / 80 induced RBL-2H3 cell degranulation in vitro model to simulate the degranulation phenomenon of mast cells in vitro, and first separates and identifies a new water-soluble phenolic acid compound (salviamarinic acid B) from the ethyl acetate part of radix salviae miltiorrhizae, which can inhibit the release of beta-Hex, reduce the levels of mMCP-1, beta-MCT, HIS and LTC4, significantly improve the degranulation phenomenon of RBL-2H3 cells, has significant anti-asthma activity, and has significant social and economic benefits.

Methods to purposefully target lytic granules to the cell membrane following NK cell activation for the benefit of bystander killing in a solid tumor setting as novel cell therapy approach. These methods can be used alone or in combination with dispersion related strategies. Methods of using truncated proteins from the dynein-dynactin complex to block dynein function to induce lytic granule dispersion. The methods and compositions enhance the lethality of degranulation events. The methods and compositions can boost cytotoxicity in a solid tumor directly or be combined with other technologies, such as immunotherapies to improve their outcomes.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and / or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and / or neuronal activation, would be therapeutically beneficial.

The invention discloses an application of a CD2 antagonist in preparation of an antituberculous drug. The preparation method comprises the following steps: targeting CD2 molecules on the surface of an NK cell by virtue of a high-affinity CD2 antagonist, synergistically strengthening the degranulation of the NK cell and the release of antibacterial peptide (granulysin, beta-defensin 4), and directly destroying the completeness of a cell membrane and a cell wall of mycobacterium tuberculosis (Mtb), so that the extracellular rapid sterilization is realized; in an in-vitro NK cell-macrophage co-culture model, the number of intracellular CFUs is remarkably reduced through the strategy; meanwhile, the mitochondrial membrane potential and metabolic activity of the NK cells are optimized, and the lasting effect is maintained; in a peripheral blood model of a tuberculosis patient, the strategy significantly amplifies Mtb-induced infected macrophage death, reduces intracellular bacterial load, integrally improves the ability of immune cells to remove infected macrophages, and provides a safe, efficient and convertible molecular intervention entry point for precise immunotherapy of tuberculosis, especially multidrug-resistant tuberculosis.

The present application belongs to the technical field of natural product extraction and cosmetic raw material preparation, and particularly relates to a roxburgh rose exosome-like nanovesicle for relieving sunburn skin inflammation and a preparation method and application thereof. In the present application, the roxburgh rose exosome-like nanovesicle is extracted by a method combining differential centrifugation and subcritical extraction technology. The content of micRNA and other active ingredients in the obtained roxburgh rose exosome-like nanovesicle can be up to 322.12 ng / μL. Even after 28 days of storage, the loss rate of active ingredients in the nanovesicle is only 2%-3%. The roxburgh rose exosome-like nanovesicle provided in the present application exhibits excellent DPPH free radical scavenging and IL-6 inflammatory factor inhibition effects. In addition, the freeze-dried powder thereof has the effect of inhibiting degranulation release when used in RBL-2H3 cells induced by IgE, and thus can be used in skin care products to better inhibit skin inflammation caused by UVB irradiation.

The invention relates to the technical field of biomedical in-vitro models, in particular to a method for constructing an airway immune response research model based on RSV infection mediation, which comprises the following steps: performing maturity authentication on an airway epithelium ALI model based on transmembrane resistance monitoring and cilia formation proportion; measuring the RSV virus titer by adopting a TCID50 method and carrying out quality authentication; co-culturing the qualified ALI model and mast cells, and dynamically calculating the required inoculation volume based on real-time virus titer to realize accurate top side infection; the functional output of the model is verified by detecting the release of epithelium-derived alarm element ATP / IL-33 and mast cell degranulation indexes. By establishing a modular quality authentication system and a dynamic parameter compensation mechanism, the technical bottlenecks of parameter solidification, large batch difference and poor repeatability in a traditional model are overcome, and a highly standardized and repeatable in-vitro research platform is provided for RSV infection mechanism research and targeted drug screening.

This invention provides a mast cell-targeting magnetoelectric hydrogel acupuncture system for acupoint stimulation, its preparation method, and its application, belonging to the technical field of biomedical materials and acupuncture-assisted treatment devices. The invention first synthesizes Fe₃O₄@BaTiO₃–FcεRIA (FBTFA) nanoparticles to achieve mast cell targeting and synergistic stimulation of cells by "mechanical force-electrical energy" under magnetic field induction. Then, it is compounded with a two-component hydrogel. The hydrogel loaded with FBTFA nanoparticles is then loaded into the groove of a threaded needle. After insertion into the local acupoint, the needle is suspended against the thread, achieving precise delivery and local retention of the hydrogel at the acupuncture site, and continuous release of nanoparticles to target subcutaneous mast cells at the acupoint. This invention generates controllable electro-mechanical stimulation under the action of an external magnetic field, inducing degranulation of rat basophilic leukemia granulocytes (RBL-2H3 cells), and achieving a sustained analgesic effect at the rat acupoint through immune-neuro-endocrine circuit regulation.